NIH Brain Development Cohorts (NBDC) and Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01 Clinical Trial Not Allowed) | PAR 27 051

FAQs: NIH PAR-27-051 (X01) Biospecimen Access from ABCD, HBCD, and PATH

What is PAR-27-051?

PAR-27-051 is an NIH funding opportunity designed to provide qualified researchers access to limited, high-value biospecimens collected through three major national studies: the Adolescent Brain Cognitive Development (ABCD) Study, the HEALthy Brain and Child Development (HBCD) Study, and the Population Assessment of Tobacco and Health (PATH) Study.

What is the main purpose of this opportunity?

The main purpose is stewardship and scientific maximization: NIH wants these finite biospecimens used for high-impact research that aligns with the goals of the parent cohorts and meaningfully extends what those studies can tell us about health across development and across the life course.

Which studies provide biospecimens under this announcement?

Biospecimens may be requested from one or more of the following parent studies: ABCD, HBCD, and PATH.

What types of research questions are considered especially responsive?

Based on the announcement description, projects are especially responsive when they use these biospecimens to deepen understanding of how genetics and environmental exposures (including exposure to substances) shape brain development, behavior, and disease risk over time. Studies that leverage the cohorts' strengths in developmental trajectories and exposure histories are particularly aligned.

What does the X01 mechanism mean in practice?

X01 is generally an access or resource-based award rather than a traditional research grant focused on providing a full project budget. In practical terms, what NIH is providing here is a permissioned, structured pathway to obtain and use biospecimens from ABCD, HBCD, and/or PATH under defined conditions, with the expectation that investigators will produce new knowledge that complements and amplifies the value of the original cohorts.

Does this opportunity provide traditional research funding?

The synopsis emphasizes that the mechanism is resource/access-oriented (X01). That implies the primary benefit is access to biospecimens via a structured process, rather than a standard grant designed to cover a full project budget.

Are clinical trials allowed under this announcement?

No. The opportunity is labeled "Clinical Trial Not Allowed." Applications should not propose a clinical trial as part of the work supported under this announcement.

How should projects be framed if clinical trials are not allowed?

Projects should be framed as research using existing biospecimens (and, where relevant, associated data), rather than interventions that prospectively assign human participants to conditions.

Why is NIH emphasizing stewardship for these samples?

The biospecimens are described as scarce, high-value, and finite. NIH is prioritizing proposals that make the best possible scientific use of these limited samples, focusing on questions that cannot be answered as well without access to these specific cohorts.

What will competitive applications need to justify?

Based on the description provided, strong applications would be expected to justify (1) why the requested specimens are essential, (2) how the proposed work fits the scientific aims of ABCD, HBCD, or PATH, and (3) how the results add value beyond what is already published or what can be done using existing public data resources alone.

Do projects need to align with the goals of the parent studies?

Yes. The central purpose is to support projects that align with each parent study's goals and meaningfully extend what those studies can reveal about health across development and across the life course.

Can an application use biospecimens from more than one parent cohort?

The announcement indicates access may be requested from ABCD, HBCD, and/or PATH, which implies proposals may target one cohort or potentially multiple cohorts, as long as the work remains aligned with the relevant parent study goals and justifies the need for the requested specimens.

Who is eligible to apply?

Eligibility is broad and includes many domestic applicant types, including: state, county, and local governments; public and private institutions of higher education; independent school districts; special district governments; public housing authorities/Indian housing authorities; tribal organizations (other than federally recognized tribal governments, as listed); nonprofit organizations (with or without 501(c)(3) status); for-profit organizations (other than small businesses); small businesses; and other eligible entities.

Are non-U.S. organizations eligible to apply?

Yes. The synopsis states that non-U.S. organizations are eligible to apply.

Are non-U.S. components of U.S. organizations eligible?

Yes. Non-U.S. components of U.S. organizations are eligible, according to the synopsis.

Are foreign components allowed?

Yes. Foreign components (as NIH defines them) are allowed, per the synopsis.

What is the key restriction on international participation?

NIH policy (as described in the synopsis) prohibits issuing awards that include foreign subawards or foreign subcontracts under this NOFO. Any application that includes foreign subawards/subcontracts will be considered noncompliant and will not be reviewed for funding.

What happens if an application includes a foreign subaward or foreign subcontract?

The synopsis states it will be considered noncompliant and will not be reviewed for funding.

Can researchers still collaborate internationally if foreign subawards/subcontracts are prohibited?

Yes, but collaborations must be structured so they do not involve foreign subawards or foreign subcontracts under this announcement. The synopsis notes the policy does not block unfunded international collaborations, allowable foreign components (as NIH defines them), paying foreign consultants (as distinct from a subaward/subcontract), or purchasing specialized equipment or supplies from foreign vendors.

Are foreign consultants allowed?

Yes. The synopsis explicitly notes that paying foreign consultants (as distinct from a subaward/subcontract arrangement) is not blocked by the policy described.

Can applicants purchase equipment or supplies from foreign vendors?

Yes. The synopsis notes that purchasing specialized equipment or supplies from foreign vendors is not blocked by the policy described.

Can unfunded international collaborations be part of the project?

Yes. The synopsis notes that unfunded international collaborations are not blocked, as long as the project remains compliant with the prohibition on foreign subawards and foreign subcontracts.

What is the agency issuing this opportunity?

The opportunity is issued by the National Institutes of Health (NIH) as a discretionary grant program.

What is the program area for this funding opportunity?

The funding activity is categorized under health and supports resource-enabled biomedical and behavioral research using biospecimens from the specified cohorts.

Which CFDA numbers are associated with this opportunity?

The synopsis lists CFDA numbers 93.121, 93.242, 93.273, 93.279, 93.399, and 93.853.

What is the closing date for this announcement?

The original closing date listed in the synopsis is April 17, 2029, indicating a multi-year window during which NIH expects to receive requests for biospecimen access.

Is there an award ceiling listed?

No award ceiling is specified in the provided synopsis.

Is the expected number of awards specified?

No. The expected number of awards is not specified in the provided synopsis, which can be typical for opportunities centered on controlled access to limited specimens.

What makes these biospecimens "high value" in this context?

The synopsis emphasizes that the samples come from three major national studies built to capture developmental trajectories and exposure histories. NIH is looking for proposals that leverage that unique value to answer questions about development, exposure (including tobacco and other substances), biology, and long-term health.

Do proposals need to show added value beyond publicly available data?

Yes. The synopsis indicates that competitive applications should explain how results will add value beyond what is already published or already possible using existing public data resources alone.

What overall kinds of outcomes is NIH trying to learn more about through these projects?

NIH is explicitly seeking to deepen understanding of brain development, behavior, and disease risk over time, especially as shaped by genetics and environmental exposures, including exposure to substances.